{Reference Type}: Journal Article
{Title}: Zanubrutinib delays selinexor resistance evolution in biopsy sample-derived primary central nervous system lymphoma models.
{Author}: Zheng X;Wang C;Chen F;Li S;Zhang H;Dong G;Yang S;Kang X;Kang Z;Han C;Yin S;Li W;
{Journal}: iScience
{Volume}: 27
{Issue}: 5
{Year}: 2024 May 17
{Factor}: 6.107
{DOI}: 10.1016/j.isci.2024.109799
{Abstract}: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma of the brain with poor prognosis. The scarcity of cell lines established using PCNSL makes it difficult to conduct preclinical studies on new drugs. We aimed to explore the effect of selinexor combined with zanubrutinib in PCNSL using established PCNSL cells and an orthotopic PCNSL model. Primary PCNSL cells were successfully cultured. Selinexor inhibited proliferation, induced G1 phase arrest, and promoted apoptosis, however, induced drug resistance in PCNSL. Selinexor combined with zanubrutinib had a synergistic effect on PCNSL and prevented the onset of selinexor resistance in PCNSL by inhibiting AKT signaling. Moreover, selinexor combined with zanubrutinib notably slowed tumor growth and prolonged survival compared to that of the control. Overall, the addition of zanubrutinib to selinexor monotreatment had a synergistic effect in vitro and prolonged survival in vivo.